Medpace Holdings Inc (NASDAQ:MEDP) – Stock analysts at William Blair upped their Q1 2018 earnings per share (EPS) estimates for shares of Medpace in a research report issued to clients and investors on Thursday. William Blair analyst J. Kreger now forecasts that the company will post earnings per share of $0.47 for the quarter, up from their prior estimate of $0.39. William Blair has a “Market Perform” rating on the stock. William Blair also issued estimates for Medpace’s Q2 2018 earnings at $0.49 EPS, Q3 2018 earnings at $0.52 EPS and Q4 2018 earnings at $0.53 EPS.
Several other analysts have also commented on MEDP. Raymond James Financial initiated coverage on Medpace in a research note on Friday, September 29th. They issued a “market perform” rating on the stock. Robert W. Baird reaffirmed a “hold” rating and issued a $32.00 price target on shares of Medpace in a research note on Monday, October 9th. KeyCorp reaffirmed a “hold” rating on shares of Medpace in a research note on Tuesday, October 17th. Zacks Investment Research lowered Medpace from a “buy” rating to a “hold” rating in a research note on Tuesday, October 24th. Finally, Jefferies Group boosted their price target on Medpace from $34.00 to $38.00 and gave the company a “hold” rating in a research note on Wednesday, November 1st. Seven research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Medpace currently has a consensus rating of “Hold” and a consensus target price of $36.60.
Shares of Medpace (NASDAQ:MEDP) opened at $37.10 on Friday. The company has a debt-to-equity ratio of 0.36, a current ratio of 0.68 and a quick ratio of 0.68. The company has a market capitalization of $1,429.96, a price-to-earnings ratio of 54.56, a P/E/G ratio of 1.69 and a beta of -1.04. Medpace has a one year low of $21.76 and a one year high of $39.64.
Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, October 30th. The company reported $0.40 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.36 by $0.04. The business had revenue of $98.68 million for the quarter, compared to analyst estimates of $96.84 million. Medpace had a return on equity of 10.00% and a net margin of 6.44%. Medpace’s quarterly revenue was up 4.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.40 EPS.
In other Medpace news, major shareholder Medpace Limited Partnership sold 4,600,000 shares of the business’s stock in a transaction on Tuesday, December 5th. The stock was sold at an average price of $30.16, for a total value of $138,736,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. 25.80% of the stock is currently owned by insiders.
Institutional investors have recently bought and sold shares of the business. First Quadrant L P CA acquired a new position in Medpace in the third quarter worth $119,000. Susquehanna International Group LLP bought a new stake in shares of Medpace during the second quarter worth $220,000. Rhumbline Advisers raised its position in shares of Medpace by 13.3% during the second quarter. Rhumbline Advisers now owns 9,726 shares of the company’s stock worth $282,000 after acquiring an additional 1,140 shares during the last quarter. GSA Capital Partners LLP bought a new stake in shares of Medpace during the second quarter worth $299,000. Finally, Parametric Portfolio Associates LLC bought a new stake in shares of Medpace during the second quarter worth $325,000. 16.80% of the stock is currently owned by institutional investors.
Medpace Company Profile
Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.